Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.99
CPHD's Cash to Debt is ranked higher than
54% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.74 vs. CPHD: 0.99 )
CPHD' s 10-Year Cash to Debt Range
Min: 0.99   Max: 11006.5
Current: 0.99

0.99
11006.5
Equity to Asset 0.47
CPHD's Equity to Asset is ranked higher than
60% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.63 vs. CPHD: 0.47 )
CPHD' s 10-Year Equity to Asset Range
Min: 0.47   Max: 0.92
Current: 0.47

0.47
0.92
F-Score: 4
Z-Score: 4.94
M-Score: -2.37
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -3.99
CPHD's Operating margin (%) is ranked higher than
65% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.84 vs. CPHD: -3.99 )
CPHD' s 10-Year Operating margin (%) Range
Min: -233.91   Max: 1.37
Current: -3.99

-233.91
1.37
Net-margin (%) -4.48
CPHD's Net-margin (%) is ranked higher than
65% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.33 vs. CPHD: -4.48 )
CPHD' s 10-Year Net-margin (%) Range
Min: -220.28   Max: 0.95
Current: -4.48

-220.28
0.95
ROE (%) -6.30
CPHD's ROE (%) is ranked higher than
63% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.27 vs. CPHD: -6.30 )
CPHD' s 10-Year ROE (%) Range
Min: -508.61   Max: 1.24
Current: -6.3

-508.61
1.24
ROA (%) -4.55
CPHD's ROA (%) is ranked higher than
64% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.84 vs. CPHD: -4.55 )
CPHD' s 10-Year ROA (%) Range
Min: -162.08   Max: 0.92
Current: -4.55

-162.08
0.92
ROC (Joel Greenblatt) (%) -10.09
CPHD's ROC (Joel Greenblatt) (%) is ranked higher than
66% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.14 vs. CPHD: -10.09 )
CPHD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -387.92   Max: 5.53
Current: -10.09

-387.92
5.53
Revenue Growth (%) 18.70
CPHD's Revenue Growth (%) is ranked higher than
94% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.80 vs. CPHD: 18.70 )
CPHD' s 10-Year Revenue Growth (%) Range
Min: -15.4   Max: 56.7
Current: 18.7

-15.4
56.7
EBITDA Growth (%) -16.20
CPHD's EBITDA Growth (%) is ranked higher than
57% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.90 vs. CPHD: -16.20 )
CPHD' s 10-Year EBITDA Growth (%) Range
Min: -38.8   Max: 8.7
Current: -16.2

-38.8
8.7
EPS Growth (%) 39.20
CPHD's EPS Growth (%) is ranked higher than
94% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.30 vs. CPHD: 39.20 )
CPHD' s 10-Year EPS Growth (%) Range
Min: -37.2   Max: 39.2
Current: 39.2

-37.2
39.2
» CPHD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

CPHD Guru Trades in Q2 2013

Columbia Wanger 8,389,000 sh (+9.43%)
Ron Baron 133,381 sh (+7.8%)
Mario Gabelli 244,500 sh (unchged)
Steven Cohen Sold Out
PRIMECAP Management 2,163,000 sh (-0.35%)
» More
Q3 2013

CPHD Guru Trades in Q3 2013

Caxton Associates 120,000 sh (New)
Ron Baron 882,500 sh (+561.64%)
Mario Gabelli 244,500 sh (unchged)
Columbia Wanger 8,389,000 sh (unchged)
PRIMECAP Management 2,147,200 sh (-0.73%)
» More
Q4 2013

CPHD Guru Trades in Q4 2013

PRIMECAP Management 2,179,200 sh (+1.49%)
Ron Baron 882,500 sh (unchged)
Caxton Associates Sold Out
Columbia Wanger 8,360,000 sh (-0.35%)
Mario Gabelli 238,500 sh (-2.45%)
» More
Q1 2014

CPHD Guru Trades in Q1 2014

PRIMECAP Management 2,270,400 sh (+4.19%)
Ron Baron 889,830 sh (+0.83%)
Mario Gabelli 235,500 sh (-1.26%)
Columbia Wanger 7,467,000 sh (-10.68%)
» More
» Details

Insider Trades

Latest Guru Trades with CPHD

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ron Baron 2013-09-30 Add 561.64%0.14%$33.66 - $39.31 $ 41.5515%882500
Ron Baron 2012-12-31 New Buy0.03%$28.72 - $35.71 $ 41.5529%123586
George Soros 2011-09-30 Sold Out 0.0029%$30.18 - $40.77 $ 41.5519%0
George Soros 2011-06-30 Reduce -55.97%$28.54 - $34.07 $ 41.5533%5900
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 8.20
CPHD's P/B is ranked higher than
61% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.79 vs. CPHD: 8.20 )
CPHD' s 10-Year P/B Range
Min: 2.25   Max: 21.88
Current: 8.2

2.25
21.88
P/S 6.80
CPHD's P/S is ranked higher than
64% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.55 vs. CPHD: 6.80 )
CPHD' s 10-Year P/S Range
Min: 2.19   Max: 21.88
Current: 6.8

2.19
21.88
EV-to-EBIT -126.88
CPHD's EV-to-EBIT is ranked higher than
70% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. CPHD: -126.88 )
CPHD' s 10-Year EV-to-EBIT Range
Min: 285.6   Max: 744.4
Current: -126.88

285.6
744.4
Current Ratio 4.52
CPHD's Current Ratio is ranked higher than
82% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.67 vs. CPHD: 4.52 )
CPHD' s 10-Year Current Ratio Range
Min: 1.49   Max: 15.23
Current: 4.52

1.49
15.23
Quick Ratio 3.36
CPHD's Quick Ratio is ranked higher than
78% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.49 vs. CPHD: 3.36 )
CPHD' s 10-Year Quick Ratio Range
Min: 0.89   Max: 14.9
Current: 3.36

0.89
14.9

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 9.60
CPHD's Price/Tangible Book is ranked higher than
66% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.20 vs. CPHD: 9.60 )
CPHD' s 10-Year Price/Tangible Book Range
Min: 2.1   Max: 20.68
Current: 9.6

2.1
20.68
Price/DCF (Projected) 18.60
CPHD's Price/DCF (Projected) is ranked higher than
80% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. CPHD: 18.60 )
CPHD' s 10-Year Price/DCF (Projected) Range
Min: 16.87   Max: 72.17
Current: 18.6

16.87
72.17
Price/Median PS Value 1.00
CPHD's Price/Median PS Value is ranked higher than
83% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.41 vs. CPHD: 1.00 )
CPHD' s 10-Year Price/Median PS Value Range
Min: 0.45   Max: 4.03
Current: 1

0.45
4.03
Earnings Yield (Greenblatt) 0.20
CPHD's Earnings Yield (Greenblatt) is ranked lower than
62% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.20 vs. CPHD: 0.20 )
CPHD' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 0.4
Current: 0.2

0.1
0.4
Forward Rate of Return (Yacktman) -0.22
CPHD's Forward Rate of Return (Yacktman) is ranked higher than
70% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.93 vs. CPHD: -0.22 )
CPHD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -1.2   Max: -0.9
Current: -0.22

-1.2
-0.9

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:XEP.Germany
Cepheid was incorporated in the State of California on March 4, 1996. The Company is a molecular diagnostics company that develops, manufactures and markets integrated systems for testing in the clinical market, as well as for application in its non-clinical markets. The Company's systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The Company's product portfolio consists of tests, reagents and systems for the clinical and non-clinical markets. The Company's two systems are the GeneXpert and SmartCycler. The GeneXpert system, offers services in the clinical market, integrates sample preparation in addition to DNA amplification and detection. The GeneXpert system is designed for user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals and doctors' offices. The SmartCycler system integrates DNA amplification and detection to allow rapid analysis of a sample.
» More Articles for CPHD

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: SeaCube, Hasbro, Cepheid, Honeywell Apr 28 2013 
Weekly CFO Sales Highlight: CLB, CPHD, ALXN, RDEA, BCR Jul 31 2011 
CEPHEID (CPHD) SVP, CFO Andrew Miller sells 2,500 Shares Feb 28 2011 
CEPHEID Reports Operating Results (10-K) Feb 24 2011 
CEPHEID (CPHD) SVP, CFO Andrew Miller sells 2,500 Shares Feb 15 2011 
CEPHEID (CPHD) SVP, CFO Andrew Miller sells 2,500 Shares Feb 08 2011 
CEPHEID (CPHD) SVP, CFO Andrew Miller sells 10,000 Shares Dec 09 2010 
CEPHEID Reports Operating Results (10-Q) Nov 04 2010 
CEPHEID Reports Operating Results (10-Q) Aug 04 2010 
CEPHEID Reports Operating Results (10-Q) May 04 2010 


More From Other Websites
Cepheid Slumps: CPHD Tumbles 9.3% in Session Jul 21 2014
Cepheid Posts Narrower-than-Expected Q2 Loss, Revenues Rise Jul 18 2014
Cepheid says Roche patent suit will not have material adverse impact on results Jul 17 2014
CEPHEID Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and... Jul 17 2014
Cepheid Reports 2014 Second Quarter Results Jul 17 2014
Q2 2014 Cepheid Earnings Release - After Market Close Jul 17 2014
Cepheid Q2 results should beat expectations, says Wedbush Jul 14 2014
Why Cepheid (CPHD) Might Surprise This Earnings Season Jul 14 2014
Cepheid Schedules 2014 Second Quarter Results Announcement And Webcast Jul 03 2014
Cepheid Schedules 2014 Second Quarter Results Announcement And Webcast Jul 03 2014
Cepheid Developing A Rapid Diagnostic Test For Multidrug-Resistant Superbugs Jun 29 2014
Cepheid Forms Pharma Alliance to Fight Antibiotic Resistance Jun 23 2014
Cepheid And Leading Pharmaceutical Companies Partner On A Diagnostic Test To Help Tackle... Jun 19 2014
Cepheid Announces European Release of Xpert Carba-R, a Molecular Test for Rapid and Accurate... Jun 16 2014
CEPHEID Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial... Jun 09 2014
Cepheid Welcomes Executive Vice President Of International Commercial Operations Jun 09 2014
Cepheid upgraded at Needham May 27 2014
Cepheid upgraded to Buy from Hold at Needham May 27 2014
Cepheid upgraded by Needham May 27 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide